Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells $115,198.05 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,885 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $115,198.05. Following the completion of the transaction, the chief operating officer now directly owns 168,327 shares in the company, valued at $6,721,297.11. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, July 23rd, Patrick John Finn sold 2,207 shares of Twist Bioscience stock. The shares were sold at an average price of $56.62, for a total value of $124,960.34.
• On Tuesday, July 2nd, Patrick John Finn sold 476 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $22,848.00.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $1.45 during trading on Friday, hitting $43.97. 944,659 shares of the company’s stock traded hands, compared to its average volume of 1,050,882. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90. The company has a market cap of $2.58 billion, a PE ratio of -13.09 and a beta of 1.80. The firm’s fifty day moving average price is $50.93 and its 200 day moving average price is $41.70.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.01) earnings per share. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TWST. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. TD Cowen increased their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Scotiabank increased their price objective on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday, May 6th. Finally, The Goldman Sachs Group boosted their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the fourth quarter worth about $30,000. Blue Trust Inc. grew its position in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the 2nd quarter worth approximately $61,000. Nisa Investment Advisors LLC increased its holdings in Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares in the last quarter. Finally, CWM LLC raised its position in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.